SNAPShot Learning: Update on GLP-1 receptor agonist availability
Date: 15 June 2021
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have several clinical benefits for patients with type 2 diabetes, including robust glycaemic efficacy, weight loss, and cardiovascular benefits.1,2
From 1st August 2021, Bydureon® (exenatide XR) will no longer be available in Australia due to the discontinuation of global supply.
Guild Learning and Development has developed a short SNAPShot Learning course titled Update on GLP-1 receptor agonist availability for type 2 diabetes.
This course discusses what the discontinuation means for patients and how you can assist them to transition to other GLP-1 receptor agonists for their type 2 diabetes management. It also reviews the use and place in therapy of GLP-1RAs in the management of type 2 diabetes.
This course will take about 15 minutes to complete. It is not CPD accredited but pharmacists can self-record using the 'self-record' function.
To enrol in this course please visit guilded.guild.org.au
Please contact Guild Learning and Development on 1800 049 056 or email learninganddevelopment@guild.org.au for more information.
- Lovshin JA. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. Can J Diabetes. 2017;41(5):524-35.
- Handelsman Y, Wyne K, Cannon A, Shannon M, Schneider D. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. JMCP. 2018;24(9-a):14-29.
Contact: Peter Waterman
Phone: 0419 260 827
Page last updated on: 16 February 2022